AtriCure Q2 2026 revenue $153.6M (+12.8% YoY); net income $9.0M vs loss a year ago

AtriCure, Inc.

Worldwide revenue $153.6M, up 12.8% YoY (12.4% constant currency); U.S. revenue $125.6M (+13.6%).
Net income $9.0M ($0.18 EPS) vs net loss of $0.13 per share in Q2 2025; adjusted EBITDA $27.3M (+78%).
Gross margin 77.2%, up 269 bps YoY; income from operations $9.7M vs loss of $6.2M.
Growth driven by cryoSPHERE MAX pain management probe, EnCompass clamp, AtriClip devices; international revenue $28.0M (+9.6%).
Advancing BoxX-NoAF and LeAAPS clinical trials towards data readouts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.